K., Nomura, S., Baek, Y., Choi, H
This timely review explores the growing role of GLP-1 receptor agonists (such as semaglutide and tirzepatide) in breast cancer care and survivorship
Vlt toistuvaa jdyttmist ja sulatusta
Why this matters: Tirzepatide alone already very powerful (15-22%) May already be optimizing GIP/GLP-1 pathways maximally Adding amylin might only add 2-5% more weight loss But could significantly increase side effects Risk-benefit ratio unknown Contrast with CagriSema: CagriSema: Extensively studied, Phase 3 trials, known safety Tirzepatide + cagrilintide: Zero studies, no safety data, speculative Learn about evidence-based approaches at SeekPeptides - explore best peptides for weight loss and best peptide stack for weight loss
The Science-Backed Benefits of MIC+B12 Injection ENERGY & METABOLISM Reignite your energy and support a faster, healthier metabolism